Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Weekes

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Nature Reviews. Clinical Oncology|April 18, 2012
Patient-derived tumour xenografts as models for oncology drug developmentJohn J Tentler, Aik Choon Tan, Colin D Weekes, et al.
Plos One|March 23, 2013
Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancerErica L Bradshaw-Pierce, Todd M Pitts, Gillian Kulikowski, et al.
Investigational New Drugs|March 15, 2012
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancerA Dasari, L Gore, W A Messersmith, et al.
Neoplasia (New York, N.Y.)|September 7, 2012
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancerColin D Weekes, Dongweon Song, John Arcaroli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2010
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancerJeffrey R Infante, Suzanne F Jones, Johanna C Bendell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2012
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancerWen Wee Ma, Wells A Messersmith, Grace K Dy, et al.
Oncotarget|January 1, 2017
CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogrammingAgnieszka A Kendrick, Johnathon Schafer, Monika Dzieciatkowska, et al.
Cancer|November 8, 2012
Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinomaManon Buijs, Diane K Reyes, Timothy M Pawlik, et al.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimenColin D Weekes, Julie M Vose, Jim C Lynch, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Nature Reviews. Clinical Oncology|April 18, 2012
Patient-derived tumour xenografts as models for oncology drug developmentJohn J Tentler, Aik Choon Tan, Colin D Weekes, et al.
Plos One|March 23, 2013
Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancerErica L Bradshaw-Pierce, Todd M Pitts, Gillian Kulikowski, et al.
Investigational New Drugs|March 15, 2012
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancerA Dasari, L Gore, W A Messersmith, et al.
Neoplasia (New York, N.Y.)|September 7, 2012
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancerColin D Weekes, Dongweon Song, John Arcaroli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2010
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancerJeffrey R Infante, Suzanne F Jones, Johanna C Bendell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2012
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancerWen Wee Ma, Wells A Messersmith, Grace K Dy, et al.
Oncotarget|January 1, 2017
CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogrammingAgnieszka A Kendrick, Johnathon Schafer, Monika Dzieciatkowska, et al.
Cancer|November 8, 2012
Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinomaManon Buijs, Diane K Reyes, Timothy M Pawlik, et al.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimenColin D Weekes, Julie M Vose, Jim C Lynch, et al.
Pageof 7